Incidence of adverse cardiac events 5 years after polymer‐free sirolimus eluting stent implantation: Results from the prospective Bad Berka Yukon Choice™ registry. Issue 7 (12th November 2013)

• Record Type: Journal Article
• Authors: Ohlow, Marc‐Alexander; von Korn, Hubertus; Gunkel, Oliver; Farah, Ahmed; Fuhrmann, Joerg T.; Lauer, Bernward
• Is Part Of: Catheterization and cardiovascular interventions. Volume 84:Issue 7(2014:Dec. 01)
• Page Start: 1080
• Page End: 1086
• Publication Date: 2013-11-12
• Subjects: Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.25272
• Languages: English
• ISSNs: 1522-1946

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ccd25272-sec-0001" sec-type="section"> <title>Objectives</title> <p>Drug‐eluting stents (DES) constitute a major achievement in preventing re‐stenosis, concerns remain regarding the increased inflammatory responses associated with the polymers used. This analysis focuses on outcomes in patients receiving the polymer‐free sirolimus‐eluting stent system YUKON‐Choice (Yukon‐DES, Translumina, Germany).</p> </sec> <sec id="ccd25272-sec-0002" sec-type="section"> <title>Methods</title> <p>From 01/2006‐09/2008 all patients receiving Yukon‐DES (≥2.5 mm diameter) were prospectively enrolled in our registry. The primary endpoint was long‐term major adverse cardiac events (MACE).</p> </sec> <sec id="ccd25272-sec-0003" sec-type="section"> <title>Results</title> <p>701 patients were included in our registry. Mean age was 65.7 ± 10 years (73% male gender, 35.5% diabetes, and 32.2% acute coronary syndrome). 76% of the lesions were of Type B2/C. Lesion length was 24.6 ± 5.2 mm and mean stent diameter was 2.8 ± 0.4 mm. A total of 511 pts (72%) underwent 6‐months angiographic follow‐up, target vessel revascularization was noted in 23.5%. At 5 years clinical outcomes were: cardiac death 5.8%; myocardial infarction 3.4%; and TVR 24.6%. The incidence of MACE differed significantly between "on‐label" and "off‐label" indications (14.8% vs. 40.8% MACE; <italic>P</italic> < 0.001). Incidence of definitive/probable stent thrombosis (ST) was 1.14% (8/701); very late (>1 year) ST occurred in 0.29%.</p> </sec> <sec id="ccd25272-sec-0004" sec-type="section"> <title>Conclusion</title> <p>Our data suggests that the implantation of the sirolimus‐coated polymer‐free YUKON‐DES is safe and feasible with a very low incidence of ST in this real world patient cohort with high percentage of diabetes and small vessels. © 2013 Wiley Periodicals, Inc.</p> </sec> </abstract>